Ujjal Didar Singh Sekhon/LinkedIn
Jul 28, 2026, 08:28
Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
Ujjal Didar Singh Sekhon, Director of Research Development at Haima Therapeutics, shared a post on LinkedIn:
“ISTH 2026 was a privilege to be part of: pathbreaking research, illuminating conversations, and a dose of Paris on top.
I was honored to present our work advancing SynthoPlate through models of P2Y12 blockade.
A huge thanks to the Haima team behind this milestone, and to the colleagues who came by with questions and suggestions that will sharpen what comes next.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils